The treatment of chronic kidney disease (CKD), including the provision of dialysis and transplant services, is a major public health matter. CKD also has substantial economic and social impacts on patients and on health care expenditure by Queensland Health. This presentation will give an overview of the Advancing Kidney Care 2026 Collaborative (AKC2026) and project work which has been undertaken over the past year. AKC2026 has the aim of supporting greater equity of access and uniformity of treatment for people with CKD, irrespective of where they live in Queensland.

AKC2026 was established in late 2018 following a commissioned external review of Queensland public renal services by Professor Adeera Levin, and has a governance approach that is setting new benchmarks in respect to consumer engagement and collaboration across disciplines and Queensland Health.

Consumer representatives have had an important role in the development of AKC2026 priorities and in the content of *The Queensland Health framework delivering quality care to people with kidney disease*, including its seven chapters on renal care and their affiliated quality statements. Consumer representation on each working group helped capture “what is important to patients and their carer(s) from their kidney care providers”.

*The Framework*, planned for endorsement in August this year, is a foundational AKC2026 product and informs current and future collaborative priorities. These priorities include establishing a digitally integrated kidney care data solution and investigating options for an alternative state renal funding model. Other priorities include a renal service mapping and gap analysis and monitoring of the release of $10M in recurrent funding to kidney priority areas from this financial year.

This presentation provides a platform to update Queensland RSA members on AKC2026, but importantly, an opportunity to also to say thanks and acknowledge the great support provided by our society colleagues in enabling the program.